Solventum Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
9.8%projected annual EPS growth
Analyst Coverage
13analysts covering
FY EPS (est.)
$7.18next fiscal year
Monitoring Framework
Key Performance Indicators
Organic Sales Growth Quarterly210.0%Target: 2.0% to 3.0%
Adjusted Diluted EPS Quarterly1.5Target: Toward the high end of $6.40 to $6.60
Free Cash Flow AnnuallyTarget: ~$200M
Watch Items
- ERP Migration and IT Separation from 3MTrigger: Delays in cutover schedules or cost overruns exceeding the $450M-$500M separation budgetAction: Re-evaluate short-term operating margin targets and adjust stand-alone cash flow projections.
- Tariff HeadwindsTrigger: Impact exceeding the budgeted $100M–$120M range built into 2026 guidanceAction: Assess pricing power across MedSurg and Dental segments to offset incremental cost pressures.
Research as of 2 Sep 2026